SlideShare a Scribd company logo
1 of 36
ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS Barry K Logan PhD, DABFT National Director of Forensic Services, NMS Labs Willow Grove PA
Disclaimer ,[object Object]
Current Options in Drug Testing
Drug Testing: Current Approaches  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Drug Testing: Current Approaches  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Drug Testing: Current Approaches  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Drugs in Oral Fluid
Oral Fluid ,[object Object],[object Object],[object Object],[object Object]
Cocaine in Oral Fluid  150 mg/70 kg sc cocaine, (N=14 oral fluid) (N=13 plasma) Courtesy, Marilyn Huestis, NIDA
THC in Oral Fluid Courtesy, Marilyn Huestis, NIDA Hours 0.01 0.1 1 10 100 1000 10000 0 1 10 100 Oral Fluid Plasma 3.55%THC GC-MS ng/mL or ng/mg
Methamphetamine in Oral Fluid 0 20 40 60 80 Low Dose High Dose Hours Oral fluid (cutoffs 50 Meth/2.5 Amp) Urine (cutoffs 500Meth/200 Amp) Courtesy, Marilyn Huestis, NIDA
History of OF Drug Testing
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],History of OF Drug Testing
[object Object],[object Object],[object Object],[object Object],[object Object],History of OF Drug Testing
DUID Oral Fluid Use Belgium: saliva screening, blood/saliva confirmation Australia: saliva screening (2x), saliva confirmation Germany: saliva/urine testing, blood confirmation UK: FST, blood sampling; no device being used France: saliva screening, blood confirmation Switzerland: Approved for use
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Drug Testing Around the World
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Drug Testing Around the World
DUID Oral Fluid Use United States: OF Specifically Approved in: Alabama Arizona Colorado Indiana Kansas Louisiana Missouri New York North Carolina North Dakota Ohio Oregon South Dakota Utah Canada: OF Approved in Federal Legislation
Cut-Offs - Amphetamines ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
OF Workplace Testing in the US ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
US National Roadside Survey 2007
2007 US National Roadside Survey ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Sample Collection ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
2007 US NRS Scope ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
2007 National Roadside Survey ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
2007 National Roadside Survey ,[object Object],[object Object],[object Object],Drug Positivity THC 8.65% Cocaine 3.92% Hydrocodone 0.68% Oxycodone 0.82% Alprazolam 0.64% Methamphetamine 0.84% Sertraline 0.50% Propoxyphene 0.52% Tramadol 0.46% Diazepam 0.38% Amphetamine 0.45% Fluoxetine 0.37% Phentermine 0.26% Dextromethorphan 0.22% Methadone 0.19%
2007 NRS - OF Positivity
2007 NRS - Paired Specimens ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
2007 NRS - Paired Specimens ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Most common exact matches
Implementing OF Testing
Making OF Testing work for DRE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Making OF Testing work for DRE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Making OF Testing work for DRE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Making OF Testing work for DRE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Summary ,[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

Similar to Oral Fluid as a Chemical Test for the DRE Program

Analytical Considerations When Monitoring Pain Medications by LC-MS/MS
Analytical Considerations When Monitoring Pain Medications by LC-MS/MSAnalytical Considerations When Monitoring Pain Medications by LC-MS/MS
Analytical Considerations When Monitoring Pain Medications by LC-MS/MS
David Masters-Moore
 
Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]
Eugene Elwell
 
Computational Toxicity in 21st Century Safety Sciences
Computational Toxicity in 21st Century Safety SciencesComputational Toxicity in 21st Century Safety Sciences
Computational Toxicity in 21st Century Safety Sciences
U.S. EPA Office of Research and Development
 
Dui d in urine poster itsp
Dui d in urine poster itspDui d in urine poster itsp
Dui d in urine poster itsp
Mark Hayward
 
Art%3 a10.1007%2fs12161 013-9618-4
Art%3 a10.1007%2fs12161 013-9618-4Art%3 a10.1007%2fs12161 013-9618-4
Art%3 a10.1007%2fs12161 013-9618-4
Nádia Paracampo
 
Application of Computational and High-Throughput in vitro Screening for Prior...
Application of Computational and High-Throughput in vitro Screening for Prior...Application of Computational and High-Throughput in vitro Screening for Prior...
Application of Computational and High-Throughput in vitro Screening for Prior...
U.S. EPA Office of Research and Development
 
Unified-Drug-Analysis_Hayward_HPLC-2016
Unified-Drug-Analysis_Hayward_HPLC-2016Unified-Drug-Analysis_Hayward_HPLC-2016
Unified-Drug-Analysis_Hayward_HPLC-2016
Mark Hayward
 
CoMPARA: Collaborative Modeling Project for Androgen Receptor Activity
CoMPARA: Collaborative Modeling Project for Androgen Receptor ActivityCoMPARA: Collaborative Modeling Project for Androgen Receptor Activity
CoMPARA: Collaborative Modeling Project for Androgen Receptor Activity
Kamel Mansouri
 
Solaris bio cellular analysis
Solaris bio cellular analysisSolaris bio cellular analysis
Solaris bio cellular analysis
zmusial
 
2014-Yeo-A Multiplex Two-Color Real-Time PCR Method(1)
2014-Yeo-A Multiplex Two-Color Real-Time PCR Method(1)2014-Yeo-A Multiplex Two-Color Real-Time PCR Method(1)
2014-Yeo-A Multiplex Two-Color Real-Time PCR Method(1)
Ji-Youn Yeo
 

Similar to Oral Fluid as a Chemical Test for the DRE Program (20)

Developments in Toxicology Support for the DRE Community
Developments in Toxicology Support for the DRE CommunityDevelopments in Toxicology Support for the DRE Community
Developments in Toxicology Support for the DRE Community
 
Analytical Considerations When Monitoring Pain Medications by LC-MS/MS
Analytical Considerations When Monitoring Pain Medications by LC-MS/MSAnalytical Considerations When Monitoring Pain Medications by LC-MS/MS
Analytical Considerations When Monitoring Pain Medications by LC-MS/MS
 
Systematic sampling approach reveals fewer falsified first line antimalarials...
Systematic sampling approach reveals fewer falsified first line antimalarials...Systematic sampling approach reveals fewer falsified first line antimalarials...
Systematic sampling approach reveals fewer falsified first line antimalarials...
 
Workplace Drug Screening Using Liquid Chromatography-Tandem Mass Spectrometry...
Workplace Drug Screening Using Liquid Chromatography-Tandem Mass Spectrometry...Workplace Drug Screening Using Liquid Chromatography-Tandem Mass Spectrometry...
Workplace Drug Screening Using Liquid Chromatography-Tandem Mass Spectrometry...
 
Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]
 
Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]
 
Computational Toxicity in 21st Century Safety Sciences
Computational Toxicity in 21st Century Safety SciencesComputational Toxicity in 21st Century Safety Sciences
Computational Toxicity in 21st Century Safety Sciences
 
Role of instrumentation in Pharmacology
Role of instrumentation in PharmacologyRole of instrumentation in Pharmacology
Role of instrumentation in Pharmacology
 
DUI-D in Urine Poster
DUI-D in Urine PosterDUI-D in Urine Poster
DUI-D in Urine Poster
 
Dui d in urine poster itsp
Dui d in urine poster itspDui d in urine poster itsp
Dui d in urine poster itsp
 
Ultra performance liquid chromatographic method for simultaneous quantificati...
Ultra performance liquid chromatographic method for simultaneous quantificati...Ultra performance liquid chromatographic method for simultaneous quantificati...
Ultra performance liquid chromatographic method for simultaneous quantificati...
 
Understanding Bioanalytical Method Validation in a Regulatory Perspective
Understanding Bioanalytical Method Validation in a Regulatory PerspectiveUnderstanding Bioanalytical Method Validation in a Regulatory Perspective
Understanding Bioanalytical Method Validation in a Regulatory Perspective
 
Art%3 a10.1007%2fs12161 013-9618-4
Art%3 a10.1007%2fs12161 013-9618-4Art%3 a10.1007%2fs12161 013-9618-4
Art%3 a10.1007%2fs12161 013-9618-4
 
High throughput screening
High throughput screeningHigh throughput screening
High throughput screening
 
EVALUATION SEMINAR ON FORENSIC TOXICOLOGY
EVALUATION SEMINAR ON FORENSIC TOXICOLOGYEVALUATION SEMINAR ON FORENSIC TOXICOLOGY
EVALUATION SEMINAR ON FORENSIC TOXICOLOGY
 
Application of Computational and High-Throughput in vitro Screening for Prior...
Application of Computational and High-Throughput in vitro Screening for Prior...Application of Computational and High-Throughput in vitro Screening for Prior...
Application of Computational and High-Throughput in vitro Screening for Prior...
 
Unified-Drug-Analysis_Hayward_HPLC-2016
Unified-Drug-Analysis_Hayward_HPLC-2016Unified-Drug-Analysis_Hayward_HPLC-2016
Unified-Drug-Analysis_Hayward_HPLC-2016
 
CoMPARA: Collaborative Modeling Project for Androgen Receptor Activity
CoMPARA: Collaborative Modeling Project for Androgen Receptor ActivityCoMPARA: Collaborative Modeling Project for Androgen Receptor Activity
CoMPARA: Collaborative Modeling Project for Androgen Receptor Activity
 
Solaris bio cellular analysis
Solaris bio cellular analysisSolaris bio cellular analysis
Solaris bio cellular analysis
 
2014-Yeo-A Multiplex Two-Color Real-Time PCR Method(1)
2014-Yeo-A Multiplex Two-Color Real-Time PCR Method(1)2014-Yeo-A Multiplex Two-Color Real-Time PCR Method(1)
2014-Yeo-A Multiplex Two-Color Real-Time PCR Method(1)
 

More from NMS Labs

More from NMS Labs (13)

Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases
Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone CasesIncreasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases
Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases
 
The Challenges of Analytical Method Validation for Hallucinogens and Designer...
The Challenges of Analytical Method Validation for Hallucinogens and Designer...The Challenges of Analytical Method Validation for Hallucinogens and Designer...
The Challenges of Analytical Method Validation for Hallucinogens and Designer...
 
Trends Report on Changes in the Designer Drug Market: Spring 2012
Trends Report on Changes in the Designer Drug Market: Spring 2012Trends Report on Changes in the Designer Drug Market: Spring 2012
Trends Report on Changes in the Designer Drug Market: Spring 2012
 
The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...
The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...
The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...
 
Pharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids
Pharmacodynamics and Pharmacokinetics of Synthetic CannabinoidsPharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids
Pharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids
 
Designer Drugs Testing Solutions for Employers
Designer Drugs Testing Solutions for EmployersDesigner Drugs Testing Solutions for Employers
Designer Drugs Testing Solutions for Employers
 
K2 and Beyond: A Synthetic Cannabinoid Primer
K2 and Beyond: A Synthetic Cannabinoid PrimerK2 and Beyond: A Synthetic Cannabinoid Primer
K2 and Beyond: A Synthetic Cannabinoid Primer
 
K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis
K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical AnalysisK2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis
K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis
 
Salvia: Effects, Legal Status and Analysis
Salvia: Effects, Legal Status and AnalysisSalvia: Effects, Legal Status and Analysis
Salvia: Effects, Legal Status and Analysis
 
New Highs: Salvia and K 2 - Solutions for the DRE
New Highs: Salvia and K 2 - Solutions for the DRENew Highs: Salvia and K 2 - Solutions for the DRE
New Highs: Salvia and K 2 - Solutions for the DRE
 
Testing for BPA and other EDCs
Testing for BPA and other EDCsTesting for BPA and other EDCs
Testing for BPA and other EDCs
 
NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10
NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10
NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10
 
NMS Labs introduction
NMS Labs introductionNMS Labs introduction
NMS Labs introduction
 

Recently uploaded

Sonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptxSonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptx
palsonia139
 

Recently uploaded (20)

5cladba raw material 5CL-ADB-A precursor raw
5cladba raw material 5CL-ADB-A precursor raw5cladba raw material 5CL-ADB-A precursor raw
5cladba raw material 5CL-ADB-A precursor raw
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptx
 
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptxSURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answers
 
World Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptWorld Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 ppt
 
Creating Accessible Public Health Communications
Creating Accessible Public Health CommunicationsCreating Accessible Public Health Communications
Creating Accessible Public Health Communications
 
Presentació "Advancing Emergency Medicine Education through Virtual Reality"
Presentació "Advancing Emergency Medicine Education through Virtual Reality"Presentació "Advancing Emergency Medicine Education through Virtual Reality"
Presentació "Advancing Emergency Medicine Education through Virtual Reality"
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
 
Pharmacology of drugs acting on Renal System.pdf
Pharmacology of drugs acting on Renal System.pdfPharmacology of drugs acting on Renal System.pdf
Pharmacology of drugs acting on Renal System.pdf
 
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt)  CAS 5449-12-7 Pharmaceutical intermediatesBMK Glycidic Acid (sodium salt)  CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
 
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالةGallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
 
Sonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptxSonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptx
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
 
Denture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of actionDenture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of action
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptx
 
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...
 
Integrated Neuromuscular Inhibition Technique (INIT)
Integrated Neuromuscular Inhibition Technique (INIT)Integrated Neuromuscular Inhibition Technique (INIT)
Integrated Neuromuscular Inhibition Technique (INIT)
 
Hepar Sulphuris Remedy, Homoeopathic Materia Medica, HMM, 1st BhMS
Hepar Sulphuris Remedy, Homoeopathic Materia Medica, HMM, 1st BhMSHepar Sulphuris Remedy, Homoeopathic Materia Medica, HMM, 1st BhMS
Hepar Sulphuris Remedy, Homoeopathic Materia Medica, HMM, 1st BhMS
 
Scleroderma: Treatment Options and a Look to the Future - Dr. Macklin
Scleroderma: Treatment Options and a Look to the Future - Dr. MacklinScleroderma: Treatment Options and a Look to the Future - Dr. Macklin
Scleroderma: Treatment Options and a Look to the Future - Dr. Macklin
 

Oral Fluid as a Chemical Test for the DRE Program

  • 1. ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS Barry K Logan PhD, DABFT National Director of Forensic Services, NMS Labs Willow Grove PA
  • 2.
  • 3. Current Options in Drug Testing
  • 4.
  • 5.
  • 6.
  • 8.
  • 9. Cocaine in Oral Fluid 150 mg/70 kg sc cocaine, (N=14 oral fluid) (N=13 plasma) Courtesy, Marilyn Huestis, NIDA
  • 10. THC in Oral Fluid Courtesy, Marilyn Huestis, NIDA Hours 0.01 0.1 1 10 100 1000 10000 0 1 10 100 Oral Fluid Plasma 3.55%THC GC-MS ng/mL or ng/mg
  • 11. Methamphetamine in Oral Fluid 0 20 40 60 80 Low Dose High Dose Hours Oral fluid (cutoffs 50 Meth/2.5 Amp) Urine (cutoffs 500Meth/200 Amp) Courtesy, Marilyn Huestis, NIDA
  • 12. History of OF Drug Testing
  • 13.
  • 14.
  • 15. DUID Oral Fluid Use Belgium: saliva screening, blood/saliva confirmation Australia: saliva screening (2x), saliva confirmation Germany: saliva/urine testing, blood confirmation UK: FST, blood sampling; no device being used France: saliva screening, blood confirmation Switzerland: Approved for use
  • 16.
  • 17.
  • 18. DUID Oral Fluid Use United States: OF Specifically Approved in: Alabama Arizona Colorado Indiana Kansas Louisiana Missouri New York North Carolina North Dakota Ohio Oregon South Dakota Utah Canada: OF Approved in Federal Legislation
  • 19.
  • 20.
  • 21. US National Roadside Survey 2007
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27. 2007 NRS - OF Positivity
  • 28.
  • 29.
  • 30. Most common exact matches
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.

Editor's Notes

  1. Lipophilicity of drug Non-polar analytes (THC) partition into oral fluid more readily than polar metabolites (11-nor-9-carboxy-THC) Usually more parent drug than metabolites pKa of drug Non-ionized basic drugs in blood partition into more acidic oral fluid, become ionized & accumulate, “ion trapping of basic drugs” Molecular size of drug
  2. Median and interquartile ranges presented on log axis. Dasehed lines indicate LOQ (2.5ug/L), SAMHSA (8ug/L) and DRUID (10ug/L) oral fluid cutoffs.
  3. Time To Last Positive Methamphetamine oral fluid positive at 50 ng/mL requires 2.5 ng/mL amphetamine presence Methamphetamine urine positive at 500 ng/mL requires 200 ng/mL amphetamine presence After how many doses? After the last?